339 related articles for article (PubMed ID: 22965952)
1. Targeting mutant p53 in human tumors.
Lehmann BD; Pietenpol JA
J Clin Oncol; 2012 Oct; 30(29):3648-50. PubMed ID: 22965952
[No Abstract] [Full Text] [Related]
2. Restoration of conformation of mutant p53.
Green JA; Von Euler M; Abrahmsen LB
Ann Oncol; 2018 May; 29(5):1325-1328. PubMed ID: 29462239
[No Abstract] [Full Text] [Related]
3. Mutant p53 as a target for cancer treatment.
Duffy MJ; Synnott NC; Crown J
Eur J Cancer; 2017 Sep; 83():258-265. PubMed ID: 28756138
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological reactivation of p53 as a strategy to treat cancer.
Zawacka-Pankau J; Selivanova G
J Intern Med; 2015 Feb; 277(2):248-259. PubMed ID: 25495071
[TBL] [Abstract][Full Text] [Related]
5. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
6. Small Molecules Targeting Mutant P53: A Promising Approach for Cancer Treatment.
Lopes EA; Gomes S; Saraiva L; Santos MMM
Curr Med Chem; 2019; 26(41):7323-7336. PubMed ID: 30444195
[TBL] [Abstract][Full Text] [Related]
7. Synergistic Antitumor Effect of BKM120 with Prima-1Met Via Inhibiting PI3K/AKT/mTOR and CPSF4/hTERT Signaling and Reactivating Mutant P53.
Li Z; Xu X; Li Y; Zou K; Zhang Z; Xu X; Liao Y; Zhao X; Jiang W; Yu W; Guo W; Chen Y; Li Y; Chen M; Deng WG; Li L; Zou L
Cell Physiol Biochem; 2018; 45(5):1772-1786. PubMed ID: 29495002
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological rescue of p53 in cancer cells: the soloist meets the PRIMA donna.
Hafsi H; Hainaut P
Cell Cycle; 2011 Mar; 10(6):875-6. PubMed ID: 21358263
[No Abstract] [Full Text] [Related]
9. A balancing act: using small molecules for therapeutic intervention of the p53 pathway in cancer.
Miller JJ; Gaiddon C; Storr T
Chem Soc Rev; 2020 Oct; 49(19):6995-7014. PubMed ID: 32869798
[TBL] [Abstract][Full Text] [Related]
10. Targeting the p53 pathway.
Golubovskaya VM; Cance WG
Surg Oncol Clin N Am; 2013 Oct; 22(4):747-64. PubMed ID: 24012397
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).
Degtjarik O; Golovenko D; Diskin-Posner Y; Abrahmsén L; Rozenberg H; Shakked Z
Nat Commun; 2021 Dec; 12(1):7057. PubMed ID: 34862374
[TBL] [Abstract][Full Text] [Related]
12. Mutant p53 targeting by the low molecular weight compound STIMA-1.
Zache N; Lambert JM; Rökaeus N; Shen J; Hainaut P; Bergman J; Wiman KG; Bykov VJ
Mol Oncol; 2008 Jun; 2(1):70-80. PubMed ID: 19383329
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor p53 and its gain-of-function mutants in cancer.
Liu J; Zhang C; Feng Z
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):170-9. PubMed ID: 24374774
[TBL] [Abstract][Full Text] [Related]
14. Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer.
Lehmann S; Bykov VJ; Ali D; Andrén O; Cherif H; Tidefelt U; Uggla B; Yachnin J; Juliusson G; Moshfegh A; Paul C; Wiman KG; Andersson PO
J Clin Oncol; 2012 Oct; 30(29):3633-9. PubMed ID: 22965953
[TBL] [Abstract][Full Text] [Related]
15. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
Blandino G; Di Agostino S
J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
[TBL] [Abstract][Full Text] [Related]
16. TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong D; Kurzrock R
Mol Cancer Ther; 2016 Oct; 15(10):2475-2485. PubMed ID: 27466356
[TBL] [Abstract][Full Text] [Related]
17. Resuscitating wild-type p53 expression by disrupting ceramide glycosylation: a novel approach to target mutant p53 tumors.
Liu YY
Cancer Res; 2011 Oct; 71(20):6295-9. PubMed ID: 21972148
[TBL] [Abstract][Full Text] [Related]
18. Fortifying p53 - beyond Mdm2 inhibitors.
Sriraman A; Li Y; Dobbelstein M
Aging (Albany NY); 2016 Sep; 8(9):1836-1837. PubMed ID: 27688014
[No Abstract] [Full Text] [Related]
19. Unleash the wild type: restoration of p53 suppressive activity in skin cancer.
Madar S; Stambolsky P; Rotter V
Cell Cycle; 2011 Mar; 10(5):736-7. PubMed ID: 21311232
[No Abstract] [Full Text] [Related]
20. p53 mutations in cancer.
Muller PA; Vousden KH
Nat Cell Biol; 2013 Jan; 15(1):2-8. PubMed ID: 23263379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
